Ms. Grisewood is a Chartered Financial Analyst (CFA), who since 2014 has served as a Director, Chair of the Audit Committee and a member of the Compensation Committee of TapImmune Inc., a NASDAQ-listed public company which is a leader in the development of certain cancer treatment immunotherapies. Ms. Grisewood is also the co-founder and Director of Mobitech Regenerative Medicine, a private medical device company.
From December 2012 to June 2017, Ms. Grisewood was associated with Dawson James Securities, Inc., first as Managing Director of Corporate Finance and later as Managing Partner, Life Science Research. For a 12-year period prior to Dawson James, she led Lifesciences investment banking practices for two New York investment banks and was an independent strategic advisor for various life science companies. Ms. Grisewood has over 30 years of securities industry experience in a broad range of investment banking, advisory and research-related activities while participating in over 70 major transactions for life science and medical device companies involving initial public offerings, secondary offerings, PIPE’s and other private equity transactions, and M&A and licensing transactions.